GVK Biosciences licensed its mechanism-based toxicity database, MBT, to AstraZeneca. MBT contains over 13,000 drug and drug-like compounds, their routes of metabolism, toxic indications, and the numerical values of the measures of toxicity, according to GVK. The data has been manually curated from over 35,000 individual references, the company adds.
The license represents an extension of the existing rights to all GVK target and drug databases. The GVK databases reportedly contain over 3.2 million compounds manually curated from patents and journals and represent over 7 million quantitative SAR data points.
